drugset / Trial / NCT07028632
The Safety, Feasibility and Efficacy of NouvNeu001 for Parkinson's Disease
NaSequentialOpen-labelTreatment
Summary
This clinical trial is designed to evaluate the safety, tolerability and preliminary efficacy of a single injection of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in patients with Parkinson's disease.
Timeline
- Start
- 2025-06-30
- Primary completion
- 2026-12
- Completion
- 2030-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Human Dopaminergic Progenitor Cells | Cell therapy | — | Other |